Because FLT3 overexpression or FLT3 mutations, including FLT3-ITD (internal tandem duplication) and TKD (tyrosine kinase domain) mutations, are well-established AML drivers [10], we verified the mutational status of FLT3 in our patient cohort. This evidence concerns the gene FLT3 and acute myeloid leukemia.